Online citations, reference lists, and bibliographies.
← Back to Search

Measuring Malignant Pleural Mesothelioma

A. Nowak, S. Armato
Published 2019 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Measurement of malignant pleural mesothelioma poses significant challenges, but tumor measurement is important for clinical trials and patient prognostication. While anatomical T staging of mesothelioma currently incorporates only the extent of tumor invasion into adjacent structures, tumor burden is emerging as potentially important in this context and is the subject of current research. Assessment of the rate of change, or growth, of mesothelioma is not commonly used in clinical research, but this parameter is often informally considered in clinical practice; future research may reveal rate of tumor growth as a potentially informative prognostic indicator. Finally, the most common role for the measurement of mesothelioma is the assessment of treatment response, either in routine clinical practice or in clinical trials. Modified RECIST (mRECIST) for mesothelioma developed a process for measuring mesothelioma that is more appropriate for the unique growth pattern of this tumor, involving measurement of tumor thickness perpendicular to the chest wall or mediastinum. This process has recently been updated as mRECIST 1.1 to incorporate results of new research and to align with RECIST 1.1; mRECIST 1.1 should be used for the next generation of clinical trials in this disease.
This paper references
10.1148/radiol.2015142202
Metrology Standards for Quantitative Imaging Biomarkers.
D. Sullivan (2015)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1016/j.ejca.2008.10.028
Evaluation of lymph nodes with RECIST 1.1.
L. Schwartz (2009)
10.1007/s00330-008-0918-9
Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT
C. Plathow (2008)
10.1093/annonc/mdv387
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma.
A. Nowak (2015)
10.1016/j.ejca.2008.10.030
Validation of novel imaging methodologies for use as cancer clinical trial end-points.
D. Sargent (2009)
10.1016/j.lungcan.2015.07.011
Imaging in pleural mesothelioma: A review of the 12th International Conference of the International Mesothelioma Interest Group.
S. Armato (2015)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.1016/S1470-2045(17)30446-1
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
M. Maio (2017)
10.1378/CHEST.125.6.2356
Fluorodeoxyglucose positron emission tomography and CT after talc pleurodesis.
B. H. Kwek (2004)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1183/13993003.01428-2016
Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma
M. D. de Perrot (2017)
10.1118/1.3537610
Characterization of mesothelioma and tissues present in contrast-enhanced thoracic CT scans.
Neal A. Corson (2011)
10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
Reporting results of cancer treatment
A. Miller (1981)
10.1016/J.ACRA.2005.05.021
Evaluation of semiautomated measurements of mesothelioma tumor thickness on CT scans.
S. Armato (2005)
10.1016/S0140-6736(15)01238-6
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G. Zalcman (2016)
10.1097/JTO.0b013e318269fe21
Optimization of Response Classification Criteria for Patients with Malignant Pleural Mesothelioma
Z. Labby (2012)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
Ajcc Cancer Staging Manual. 7th Ed. New
York Springer (2010)
10.1093/JNCI/91.6.523
Measuring response in solid tumors: unidimensional versus bidimensional measurement.
K. James (1999)
10.1097/00006254-199009000-00002
The role of tumor markers in gynecologic oncology.
G. Olt (1990)
10.1007/s00259-013-2561-1
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma
A. Klabatsa (2013)
10.1200/JCO.2010.33.7071
Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.
G. Oxnard (2011)
10.1016/j.ejca.2008.10.042
Recommendations for the assessment of progression in randomised cancer treatment trials.
J. Dancey (2009)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1200/JCO.2008.26.15_SUPPL.11098
Response evaluation by CT and FDG-PET/CT in malignant pleural mesothelioma (MPM)
P. Veit-Haibach (2008)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/0169-5002(95)00508-0
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group.
V. Rusch (1996)
10.1016/j.ejca.2008.11.010
A simulation study to evaluate the impact of the number of lesions measured on response assessment.
C. Moskowitz (2009)
10.1016/S0959-8049(11)70098-3
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug (2011)
10.1016/j.jtho.2018.04.034
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
S. Armato (2018)
10.1097/JTO.0000000000000211
Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions
S. Armato (2014)
10.1016/j.ejca.2008.10.025
Cancer clinical trial outcomes: any progress in tumour-size assessment?
J. Verweij (2009)
10.1118/1.1688211
Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques.
S. Armato (2004)
10.1016/J.JCLINEPI.2003.07.015
A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
M. Mazumdar (2004)
10.1016/j.ejca.2008.10.026
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E. Eisenhauer (2009)
10.1016/j.lungcan.2013.05.006
A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
A. Nowak (2013)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1016/j.ejca.2008.10.031
Lessons learned from independent central review.
R. Ford (2009)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)
10.1093/jnci/92.3.205
New Guidelines to Evaluate the Response to Treatment in Solid Tumors.
P. Therasse (2000)
10.7150/jca.2586
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy
G. Genestreti (2012)
10.1016/J.LUNGCAN.2003.07.005
Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases.
F. Monetti (2004)
10.1016/S1470-2045(17)30074-8
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
L. Seymour (2017)
10.1016/j.lungcan.2014.11.019
Radiologic-pathologic correlation of mesothelioma tumor volume.
S. Armato (2015)
10.1016/j.ejca.2008.10.027
Individual patient data analysis to assess modifications to the RECIST criteria.
J. Bogaerts (2009)
10.1016/J.LUNGCAN.2005.12.013
Modeling of mesothelioma growth demonstrates weaknesses of current response criteria.
G. Oxnard (2006)
10.1097/JTO.0b013e31827dc74d
Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the Staging Project Database of the International Association for the Study of Lung Cancer
D. Ball (2013)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/j.jtho.2016.08.147
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
10.1016/J.LUNGCAN.2003.09.021
Staging and evaluating responses in malignant pleural mesothelioma.
G. Hillerdal (2004)
10.1016/j.jtho.2016.04.027
North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: Feasibility and Logistics of Setting Up a Quantitative Imaging Study
R. Gill (2016)
10.1097/JTO.0b013e31825f22ee
A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
A. Nowak (2012)
Serial analysis of FDG PET scans for early response evaluation in malignant pleural mesothelioma
L. Gianoncelli (2009)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1016/j.lungcan.2009.04.015
Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
P. Veit-Haibach (2010)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1183/09031936.00146110
Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?
T. Frauenfelder (2011)



Semantic Scholar Logo Some data provided by SemanticScholar